A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18F-FES […] Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor […] 21 December 2020 — AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage […] TUESDAY, Nov. 27, 2018 — Vitrakvi (larotrectinib) has been approved by the U.S. Food and Drug Administration to treat cancers […] FRIDAY, Sept. 14, 2018 — The PK Papyrus Covered Coronary Stent System has been approved by the U.S. Food and […]Approved
Newly approved PET imaging agent solves clinical dilemmas in breast cancer patients
Tagrisso approved as adjuvant therapy for NSCLC with EGFR mutations
Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
Vitrakvi (Larotrectinib) Approved for Cancers With Certain Genetic Trait
New Device Approved for Tears in Heart’s Blood Vessels
Copyright © 2024